Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  valrubicin
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-10 of 10 for your search:
Start Over
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12154, NCT01438112
Phase II Study of Intravesical AD 32 (a Doxorubicin Analogue) for in Situ Transitional Cell Carcinoma of the Bladder Refractory to BCG (Summary Last Modified 09/98)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ANTHRA-A9301/02, NCI-V95-0695
Phase II Study of Intravesical AD 32 (a Doxorubicin Analogue) for in Situ Transitional Cell Carcinoma of the Bladder with or without Prior BCG (Summary Last Modified 09/98)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ANTHRA-A9303, NCI-V95-0696
Chemotherapy in Treating Patients With Early-Stage Bladder Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000065892, E-3897, NCT00003129
Phase II Randomized Study of Peri-Operative Intravesical AD 32 Alone or Supplemented with BCG in Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ANTHRA-A9701/ID97-038, MDA-ID-97038, NCT00003759
Phase II Evaluation of Chemotherapy with AD-32 for Patients with Measurable Metastatic Malignant Disease
Phase: Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: DFCI-78061
Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-16722, NCT01606345
Retrospective Chart Review of Valstar
Phase: No phase specified
Type: Natural history/Epidemiology
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EN3329-401, NCT01304173
Start Over